22.85
전일 마감가:
$24.00
열려 있는:
$24.02
하루 거래량:
1.13M
Relative Volume:
0.81
시가총액:
$1.70B
수익:
$97.36M
순이익/손실:
$-172.42M
주가수익비율:
-9.9417
EPS:
-2.2984
순현금흐름:
$-188.84M
1주 성능:
-7.23%
1개월 성능:
-3.63%
6개월 성능:
+83.53%
1년 성능:
+52.84%
Xencor Inc Stock (XNCR) Company Profile
명칭
Xencor Inc
전화
626-305-5900
주소
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
XNCR
Xencor Inc
|
22.85 | 1.70B | 97.36M | -172.42M | -188.84M | -2.2984 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
|
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-30 | 재개 | Wells Fargo | Overweight |
| 2026-03-24 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-10-29 | 업그레이드 | Barclays | Underweight → Overweight |
| 2025-09-17 | 재개 | Barclays | Underweight |
| 2025-09-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-04-21 | 개시 | William Blair | Outperform |
| 2024-12-12 | 개시 | Wells Fargo | Overweight |
| 2024-12-02 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-04-16 | 재확인 | BTIG Research | Buy |
| 2024-02-28 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | 개시 | BofA Securities | Buy |
| 2022-12-06 | 개시 | Cowen | Outperform |
| 2022-10-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | 개시 | JP Morgan | Overweight |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-02-11 | 개시 | BMO Capital Markets | Outperform |
| 2022-01-21 | 개시 | SMBC Nikko | Outperform |
| 2021-12-15 | 개시 | H.C. Wainwright | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-02-24 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | 개시 | Barclays | Underweight |
| 2020-02-25 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-01-30 | 개시 | RBC Capital Mkts | Outperform |
| 2019-11-20 | 재개 | Guggenheim | Neutral |
| 2019-08-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-08-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-04-12 | 개시 | Guggenheim | Buy |
| 2019-03-27 | 개시 | Berenberg | Buy |
| 2019-03-15 | 개시 | Raymond James | Outperform |
| 2018-09-10 | 재개 | BTIG Research | Buy |
| 2018-03-28 | 재개 | Leerink Partners | Outperform |
| 2017-03-02 | 개시 | Instinet | Neutral |
| 2017-03-02 | 재확인 | Wedbush | Outperform |
| 2016-10-04 | 개시 | Piper Jaffray | Overweight |
| 2015-12-22 | 개시 | Canaccord Genuity | Buy |
| 2015-08-05 | 재확인 | MLV & Co | Buy |
| 2015-02-12 | 재확인 | Oppenheimer | Outperform |
| 2015-01-28 | 재확인 | MLV & Co | Buy |
| 2014-07-11 | 개시 | Oppenheimer | Outperform |
모두보기
Xencor Inc 주식(XNCR)의 최신 뉴스
Xencor, Inc. (XNCR) Stock Forecasts - Yahoo! Finance Canada
Xencor, Inc. (XNCR) Stock forecasts - Yahoo Finance UK
Xencor, Inc. (XNCR) Stock Forecasts - Yahoo Finance
Xencor Q3 2026 Earnings Date and Estimates - MarketBeat
Xencor Stock: Better Funding For Obexelimab (NASDAQ:XNCR) - Seeking Alpha
Xencor stock fell 4.96 percent as targets diverged - AD HOC NEWS
Xencor, Inc. (XNCR) Stock forecasts - Yahoo Finance UK
Trading the Move, Not the Narrative: (XNCR) Edition - Stock Traders Daily
Xencor, Inc. (XNCR) Stock Forecasts - Yahoo Finance
Xencor, Inc. (XNCR) Stock Forecasts - Yahoo Finance
Wells Fargo & Company Initiates Coverage on Xencor (NASDAQ:XNCR) - MarketBeat
Xencor stock falls 3.52 percent as Truist lifts its target - AD HOC NEWS
Xencor (NASDAQ:XNCR) Shares Climb 4.6%Should You Buy? - MarketBeat
Xencor (NASDAQ:XNCR) Earns Buy Rating from Truist Financial - MarketBeat
Truist raises Xencor stock price target to $29 on drug trial outlook - Investing.com Nigeria
Truist Securities reiterates Buy rating on Xencor, $29 price target - TradingView
Truist raises Xencor stock price target to $29 on drug trial outlook - Investing.com
Xencor, Inc. $XNCR Shares Newly Bought by Bank of America Corp DE - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Wedbush Maintains Xencor(XNCR.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Xencor, Inc. (XNCR) Stock forecasts - Yahoo Finance Singapore
Xencor, Inc. (XNCR) Stock Forecasts - Yahoo Finance
BofA Adjusts Price Target on Xencor to $26 From $20, Keeps Neutral Rating - Yahoo Finance
Xencor (XNCR) Holds Near $23.84 as Shares Consolidate Between Key LevelsATR Stop - careplusvn.com
Hsbc Holdings PLC Has $2.08 Million Position in Xencor, Inc. $XNCR - MarketBeat
Barclays Maintains Xencor(XNCR.US) With Buy Rating, Raises Target Price to $35 - moomoo.com
Xencor at 12th Annual Cantor Fitzgerald Global Healthcare Conference: late-stage shift - investing.com
Xencor at 12th Annual Cantor Fitzgerald Global Healthcare Conference: late-stage shift - Investing.com Canada
Xencor at 12th Annual Cantor Fitzgerald Global Healthcare Conference: late-stage shift - Investing.com UK
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 260,752 Shares of Xencor, Inc. $XNCR - MarketBeat
The Manufacturers Life Insurance Company Buys Shares of 49,696 Xencor, Inc. $XNCR - MarketBeat
XNCR stock holds steady as Xencor eyes next trial milestones - ad-hoc-news.de
Seven Fleet Capital Management LP Has $5.93 Million Stake in Xencor, Inc. $XNCR - MarketBeat
Man Group plc Takes Position in Xencor, Inc. $XNCR - MarketBeat
Bank of New York Mellon Corp Makes New Investment in Xencor, Inc. $XNCR - MarketBeat
XNCR Maintained by JP Morgan -- Price Target Raised to $21.00 - GuruFocus
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Xencor (NASDAQ:XNCR) Stock - MarketBeat
Technical Reactions to XNCR Trends in Macro Strategies - Stock Traders Daily
Xencor to Present at the 2026 Cantor Global Healthcare Conference - BioSpace
Xencor to Present at the 2026 Cantor Global Healthcare Conference - marketscreener.com
Xencor to Present at the 2026 Cantor Global Healthcare Conference - Business Wire
Xencor to Present at the 2026 Cantor Global Healthcare Conference - Yahoo Finance
Xencor (XNCR) Maintained by Raymond James -- Price Target Raised to $46 - GuruFocus
Raymond James Adjusts Xencor Price Target to $46 From $40, Maintains Strong Buy Rating - marketscreener.com
Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of "Hold" by Brokerages - marketbeat.com
Xencor (NASDAQ:XNCR) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Hsbc Holdings PLC Buys Shares of 125,482 Xencor, Inc. $XNCR - MarketBeat
Legal & General Group Plc Acquires Shares of 1,091,177 Xencor, Inc. $XNCR - MarketBeat
Deutsche Bank AG Acquires New Shares in Xencor, Inc. $XNCR - marketbeat.com
Bank of America Corp DE Sells 263,315 Shares of Xencor, Inc. $XNCR - marketbeat.com
Xencor Inc (XNCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Xencor Inc 주식 (XNCR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Feigal Ellen | Director |
Jun 18 '26 |
Proposed Sale |
13.06 |
6,843 |
89,370 |
0 |
| GORMAN KEVIN CHARLES | Director |
Jun 15 '26 |
Proposed Sale |
12.31 |
7,527 |
92,657 |
0 |
| GUSTAFSON KURT A | Director |
Jun 15 '26 |
Proposed Sale |
12.31 |
5,474 |
67,385 |
0 |
| RANIERI RICHARD J | Director |
Jun 15 '26 |
Proposed Sale |
12.31 |
5,474 |
67,385 |
0 |
| Montgomery Alan Bruce | Director |
Jun 15 '26 |
Proposed Sale |
12.31 |
5,064 |
62,338 |
0 |
| Montgomery Alan Bruce | Director |
Jun 15 '26 |
Sale |
12.31 |
5,064 |
62,338 |
15,547 |
| RANIERI RICHARD J | Director |
Jun 15 '26 |
Sale |
12.31 |
5,474 |
67,385 |
13,709 |
| GORMAN KEVIN CHARLES | Director |
Jun 15 '26 |
Sale |
12.31 |
7,527 |
92,657 |
11,378 |
| GUSTAFSON KURT A | Director |
Jun 15 '26 |
Sale |
12.31 |
5,474 |
67,385 |
14,709 |
| Cornelissen Bart Jan | SR. VICE PRESIDENT & CFO |
Apr 10 '26 |
Sale |
12.29 |
3,499 |
42,990 |
75,898 |
자본화:
|
볼륨(24시간):